Volume 15, Number 10—October 2009
Research
Healthcare Worker Occupation and Immune Response to Pneumocystis jirovecii
Table 2
Characteristic |
No. persons |
MsgA |
MsgB |
MsgC1 |
|||||
---|---|---|---|---|---|---|---|---|---|
GM (95% CI) |
p value |
GM (95% CI) |
p value |
GM (95% CI) |
p value |
||||
Total | 126 | 11.8 (8.1–17.0) | 2.6 (2.1–3.1) | 17.8 (13.8–22.9) | |||||
Demographics | |||||||||
Age group, y | |||||||||
<30 | 33 | 12.0 (5.4–26.8) | Ref | 2.5 (1.7–3.7) | Ref | 16.3 (9.5–28.0) | Ref | ||
31–40 | 38 | 11.0 (5.7–21.3) | 0.86 | 2.7 (1.8–3.9) | 0.84 | 22.6 (14.9–34.4) | 0.33 | ||
41–50 | 27 | 10.1 (4.5–22.4) | 0.75 | 2.4 (1.6–3.7) | 0.88 | 19.8 (11.6–33.7) | 0.61 | ||
51–60 | 21 | 17.2 (6.3–46.4) | 0.57 | 2.4 (1.4–4.2) | 0.90 | 17.4 (8.8–34.3) | 0.88 | ||
>60 | 5 | 12.8 (0.7–243.0) | 0.95 | 3.3 (0.3–32.8) | 0.66 | 4.8 (0.7–34.7) | 0.11 | ||
Sex | |||||||||
M | 54 | 14.3 (8.2–25.2) | 0.37 | 2.9 (2.1–4.0) | 0.26 | 22.7 (16.0–32.1) | 0.10 | ||
F | 72 | 10.2 (6.2–16.7) | 2.3 (1.8–3.0) | 14.8 (10.4–21.2) | |||||
Race | |||||||||
Asian | 31 | 6.6 (3.1–14.4) | 0.08 | 2.3 (1.6–3.3) | 0.49 | 27.5 (17.6–42.9) | 0.05 | ||
Other | 92 | 14.4 (9.4–22.1) | 2.7 (2.1–3.5) | 15.3 (11.2–20.7) | |||||
Ethnicity | |||||||||
Hispanic/Latino | 20 | 12.5 (5.5–28.5) | 0.92 | 1.9 (1.3–2.7) | 0.17 | 13.4 (6.2–29.1) | 0.35 | ||
Non–Hispanic/Latino |
105 |
11.9 (7.9–18.1) |
2.7 (2.2–3.5) |
18.7 (14.2–24.4) |
|||||
Health conditions | |||||||||
Smoked | |||||||||
Ever | 42 | 13.9 (7.1–27.1) | 0.58 | 2.8 (1.9–4.1) | 0.63 | 13.2 (8.4–20.9) | 0.11 | ||
Never | 83 | 11.2 (7.1–17.5) | 2.5 (2.0–3.2) | 20.5 (15.1–27.8) | |||||
Lung condition | |||||||||
Yes | 20 | 11.3 (4.4–28.7) | 0.88 | 2.5 (1.5–4.1) | 0.83 | 14.1 (7.2–27.5) | 0.45 | ||
No | 105 | 12.2 (8.1–18.3) | 2.6 (2.1–3.3) | 18.5 (14.0–24.4) | |||||
Immune condition | |||||||||
Yes | 8 | 13.1 (2.6–66.6) | 0.90 | 2.9 (0.8–10.0) | 0.76 | 24.0 (13.6–42.3) | 0.26 | ||
No |
117 |
11.9 (8.1–17.6) |
2.6 (2.1–3.1) |
17.3 (13.2–22.7) |
|||||
Professional characteristics | |||||||||
Exposed to PCP patient | |||||||||
Ever | 85 | 13.1 (8.3–20.7) | 0.41 | 2.6 (2.0–3.3) | 0.99 | 20.8 (15.8–27.3) | 0.11 | ||
Never | 41 | 9.4 (4.9–18.0) | 2.6 (1.8–3.6) | 12.9 (7.5–21.9) | |||||
Occupation | |||||||||
Clinical | 103 | 13.4 (8.9–20.1) | 0.14 | 2.6 (2.1–3.3) | 0.80 | 21.1 (16.3–27.3) | 0.004 | ||
Nonclinical | 23 | 6.6 (2.6–16.6) | 2.4 (1.5–4.0) | 8.2 (4.0–17.0) |
*Msg, major surface glycoprotein; GM, geometric mean; CI, confidence interval; Ref, reference category; PCP, P. jirovecii pneumonia. Serum antibody levels were calculated from standard curves derived by using a standard serum pool with an assigned value of 100 U; specimens below the curve were assigned the lowest possible value (1 U). Predictor variables were compared with the natural log of Msg levels using Student t test, then converted back to the original scale and presented as GM. Participants in this cross-sectional study were healthcare staff recruited during January 2007–February 2008 from San Francisco General Hospital.
Page created: December 08, 2010
Page updated: December 08, 2010
Page reviewed: December 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.